More than 1,000 U.S. ECPs can fit children in the MiSight® 1 day lens
SAN RAMON, Calif., September 9, 2020—More than 1,000 eye care professionals (ECPs) from across the United States are now certified and able to prescribe CooperVision’s Brilliant Futures™ Myopia Management Program featuring the MiSight® 1 day contact lens as its cornerstone. These practices serve children and families in 45 states.
Despite the COVID-19 pandemic striking the United States just as CooperVision launched the Brilliant Futures™ Myopia Management Program, ECPs remained eager and enthusiastic to receive training and certification. Following a pivot to online certification training, each ECP successfully completed a virtual exam and then activated their account to receive fit sets and patient starter kits. More than 350 U.S. children have already been fit in the MiSight® 1 day contact lens to date, and the number is growing daily.
CooperVision’s MiSight® 1 day contact lens is the first and only soft contact lens the U.S. Food and Drug Administration has approved* for slowing the progression of myopia in children, who at initiation of treatment are 8-12 years of age1.
“We are deeply committed to addressing the rising severity and prevalence of myopia progression worldwide, including right here in the U.S. Especially now during the current pandemic, we know children are staying inside more, often using screens, which also affects how the eye grows and develops2,3. I’m elated that so many of my fellow optometrists are eager to approach myopia management in a new way,” said Michele Andrews, OD, Senior Director of North America Professional & Academic Affairs at CooperVision. “Together, combining the innovative thinking reflected in Brilliant Futures™ with prescribers’ professional expertise, we can achieve the best possible outcomes for young patients.”
“As one of the first optometrists in the country to begin offering Brilliant Futures™ in my practice, I have already fit 9 children in the MiSight® 1 day lens,” said Roxanne Achong-Coan, OD, FAAO, FIAOMC, FSLS, at Coan Eye Care in Ocoee, Florida. “Our success is due in part to individualizing our approach to myopia management because one size does not fit all. Parents and their kids are eager to learn about the Brilliant Futures™ program. Even during the pandemic, which has brought financial constraints to many families, parents are finding a way to get their child’s myopia management plan started.”
The 45 states that currently have activated Brilliant Futures™ prescribers include: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
In addition, hundreds of other optometrists have completed their certification, and are currently in the process of fully activating their account.
Parents can find an eye doctor who is able to prescribe the Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day by visiting www.coopervision.com/find-an-eye-doctor. They simply need to add in a postal code, check the box for “pediatric nearsightedness management/Brilliant Futures™ with MiSight® 1 day” and click “search” to find an ECP closest to them.
Practices who are interested in learning more about the Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day can visit coopervision.com/practitioner/myopia-management.
* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
1 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567. Compared to a single vision 1 day lens over a 3 year period.
2 Xiaoyu Z, et al. Association between parental myopia and the risk of myopia in a child. Experimental and Therapeutic Medicine. 2015 Jun; 9(6): 2420–2428.
3 Michaud L. Too much screen time linked to an epidemic of myopia among young people. https://theconversation.com/too-much-screen-time-linked-to-an-epidemic-of-myopia-among-young-people-111599. Accessed August 20, 2020.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Jamie Palmeroni-Lavis, McDougall Communications
email@example.com or +1-585-434-2151